Attach importance to R&D and innovation, rich and complete products
As a high-tech enterprise, Aoxiang Pharmaceutical attaches great importance to product research, analysis and development. The company has a complete research and development system, including well-equipped, fully functional laboratories and scale-up verification workshops, and has the development capabilities to complete small-scale trials, optimization and scale-up production. The company’s research and development center and the Institute of Chemical Pharmaceuticals were rated as “Provincial-level High-tech Enterprise Research and Development Center” and “Provincial-level Enterprise Research Institute” by the Zhejiang Science and Technology Department, with excellent academician workstations, post-doctorate workstations, and post-doctoral innovation practice bases. The R&D platform maintains a good R&D cooperation relationship with many universities and research institutes, and plans to establish a provincial drug crystal engineering center. The company's new antihypertensive drug "Nebivolol hydrochloride bulk drug" project and the antifungal drug "Ifluconazole Innovative Process Research" project won the special acceptance certificate for key technological innovation in Zhejiang Province, and 13 products passed the provincial new product Of identification.
Through long-term accumulation, Aoxiang Pharmaceutical has a complete and rich product echelon. At present, the company's mature products have five products including CS acid and entecavir, which will provide the company with a stable source of income and profit in the next few years; at the same time, the company has completed dozens of series of raw materials including products raised for investment For the research and development of intermediates, large-scale sales can be achieved after the target drug patent expires and the generic drug is declared for listing. In addition, while researching and developing APIs and intermediates, Aoxiang Pharmaceuticals has embarked on the transformation from a single API and intermediate manufacturer to an integrated API and preparation manufacturer, and has already applied for bicyclol preparations and entecavir preparations in China. Application documents for generic drugs and 1.1-type new drug brozospray sodium raw materials and preparations. Among them, brozopentine sodium has been recommended as a priority review product by the major new drug creation technology major project implementation management office, and is expected to enter the review "green channel", which will greatly shorten the review time of new drugs. On January 18, 2016, the CFDA released the clinical approvals for the raw materials and preparations of Rozopentine sodium. After the review is passed and approved, the listing and sales of the raw materials and preparations of the 1.1-type new drug brozospray sodium will become one of the company's important sources of profit. Aoxiang Pharmaceutical has broadened the company’s business chain and the scope of cooperation with downstream customers by continuously launching new products with high technical content and high added value, helping the company establish a good image and reputation in the global pharmaceutical market, and contribute to the company’s future development. And the growth of performance provides a strong guarantee.
Strong industrialization ability, won the trust of customers
At present, Aoxiang Pharmaceuticals has established a complete R&D process and industrialization system for APIs, and has formed a chemical API production and manufacturing characterized by complete and advanced synthesis equipment, mature and rich synthesis processes, strong industrialization capabilities, and quality control specifications. Ability advantages, with chemical synthesis manufacturing capabilities for different products and a variety of special conditions. The company strictly implements the Chinese drug GMP production management specifications and the European, American and Japanese cGMP drug production management specifications. The products have passed the registration and certification of the EU GMP, the US FDA and other countries and regions, and have the ability to participate in the division and competition of the global pharmaceutical industry chain. Excellent ability and level.
Through continuous and unremitting efforts, Aoxiang Pharmaceutical has gained a high corporate reputation and reputation in the United States, Europe, Japan and other regulated markets by virtue of its high-quality product quality and strict quality control system. It has now passed a number of well-known international large-scale Qualified supplier certification of generic drugs and original research drug companies has established long-term, stable and close strategic partnerships with major customers in product development, certification, registration and production. Under the current stable major customer model, the company provides customers with APIs and intermediates process research and development, quality research and safety research services at the beginning of the project, and provides the required APIs and pharmaceutical intermediates, naturally Become a supplier of specialty APIs and pharmaceutical intermediates for customers after the products are on the market, with a relatively obvious first-mover advantage. During the service process, Aoxiang Pharmaceutical has a relatively close cooperation relationship with customers, providing the company with an excellent opportunity to contact, digest and absorb advanced technologies in the international pharmaceutical industry and learn international advanced concepts, experiences and methods in various fields, helping the company to integrate Technical capabilities and comprehensive management levels have been continuously improved.
In the future, the global pharmaceutical industry is expected to maintain rapid growth. With the expiration of a large number of "blockbuster" patented drugs, the global generic drug market will usher in rapid development. Aoxiang Pharmaceutical will use this as an opportunity to optimize and integrate the company’s existing resources, develop products with high technical difficulties and high added value, and gradually carry out the production of pharmaceutical preparations and agent processing and production for large foreign pharmaceutical pharmaceutical companies to achieve " The integrated upgrade of pharmaceutical intermediates, raw materials, and preparations will achieve the strategic goal of “serving health and building brands”, and will eventually become a first-class specialty pharmaceutical company in China.